tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Spada M et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. 2006 Am. J. Transplant. pmid:16771811
Donners MM et al. Low-dose FK506 blocks collar-induced atherosclerotic plaque development and stabilizes plaques in ApoE-/- mice. 2005 Am. J. Transplant. pmid:15888024
Lehmann R et al. Successful simultaneous islet-kidney transplantation using a steroid-free immunosuppression: two-year follow-up. 2004 Am. J. Transplant. pmid:15196070
Lemahieu W et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. 2005 Am. J. Transplant. pmid:15888045
Axelrod D et al. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients. 2005 Am. J. Transplant. pmid:15888050
Reyes J et al. Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (thymoglobulin). 2005 Am. J. Transplant. pmid:15888051
Knoop C et al. Tacrolimus pharmacokinetics and dose monitoring after lung transplantation for cystic fibrosis and other conditions. 2005 Am. J. Transplant. pmid:15888057
Kandaswamy R et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients--an interim analysis. 2005 Am. J. Transplant. pmid:15888064
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
Cosio FG and Larson TS Cardiovascular disease after transplantation: do we know all of the variables? 2003 Am. J. Transplant. pmid:12859523
Levitsky J and Feng S Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. 2014 Am. J. Transplant. pmid:24620373
Campbell PM et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. 2007 Am. J. Transplant. pmid:17456201
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Krämer BK et al. Cardiovascular risk factors and estimated risk for CAD in a randomized trial comparing calcineurin inhibitors in renal transplantation. 2003 Am. J. Transplant. pmid:12859533
Ciancio G et al. The use of daclizumab, tacrolimus and mycophenolate mofetil in african-american and Hispanic first renal transplant recipients. 2003 Am. J. Transplant. pmid:12859538
Singh K et al. Superiority of rapamycin over tacrolimus in preserving nonhuman primate Treg half-life and phenotype after adoptive transfer. 2014 Am. J. Transplant. pmid:25359003
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Tang Q Pharmacokinetics of therapeutic Tregs. 2014 Am. J. Transplant. pmid:25358900
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Trofe-Clark J et al. Immunosuppression, generic drugs and the FDA. 2012 Am. J. Transplant. pmid:22176626
Sikma MA et al. Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. 2015 Am. J. Transplant. pmid:26053114
Latran M Response to Klintmalm on the use of generic immunosuppression. 2012 Am. J. Transplant. pmid:22176636
Ellis CL and Racusen LC Mild rise in creatinine six months post kidney transplant. 2012 Am. J. Transplant. pmid:22845913
Abdelmalek MF et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. 2012 Am. J. Transplant. pmid:22233522
Boudjema K et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. 2011 Am. J. Transplant. pmid:21466650
Knechtle SJ Guidance for liver transplant immunosuppression. 2011 Am. J. Transplant. pmid:21466652
Krenzien F et al. Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus. 2017 Am. J. Transplant. pmid:27754593
Gupta G et al. Safe Conversion From Tacrolimus to Belatacept in High Immunologic Risk Kidney Transplant Recipients With Allograft Dysfunction. 2015 Am. J. Transplant. pmid:25988397
Saikali JA et al. Sirolimus may promote thrombotic microangiopathy. 2003 Am. J. Transplant. pmid:12603218
Duncan FJ et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. 2007 Am. J. Transplant. pmid:17941958
Suszynski TM et al. Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation. 2013 Am. J. Transplant. pmid:23432755
O'Grady JG et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. 2007 Am. J. Transplant. pmid:17109723
Böhmig GA et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. 2007 Am. J. Transplant. pmid:17109725
Ferguson R et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. 2011 Am. J. Transplant. pmid:21114656
Hirsch HH et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. 2013 Am. J. Transplant. pmid:23137180
Mujtaba MA et al. Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients. 2014 Am. J. Transplant. pmid:25179306
Naesens M et al. Tacrolimus exposure and evolution of renal allograft histology in the first year after transplantation. 2007 Am. J. Transplant. pmid:17608835
Koefoed-Nielsen PB et al. Blood tacrolimus levels and calcineurin phosphatase activity early after renal transplantation. 2002 Am. J. Transplant. pmid:12099520
Klintmalm GB Immunosuppression, generic drugs and the FDA. 2011 Am. J. Transplant. pmid:21794082
Shihab FS et al. Effect of corticosteroid withdrawal on tacrolimus and mycophenolate mofetil exposure in a randomized multicenter study. 2013 Am. J. Transplant. pmid:23167508
Forns X and Navasa M Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate. 2011 Am. J. Transplant. pmid:21797970
Alloway RR et al. A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. 2012 Am. J. Transplant. pmid:22759200
Wlodarczyk Z et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. 2009 Am. J. Transplant. pmid:19681813
Chisholm-Burns MA et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. 2009 Am. J. Transplant. pmid:19681814
Schold JD and Kaplan B AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. 2009 Am. J. Transplant. pmid:19681827
Troppmann C et al. Impact of portal venous pancreas graft drainage on kidney graft outcome in simultaneous pancreas-kidney recipients reported to UNOS. 2004 Am. J. Transplant. pmid:15023146
Pirenne J et al. Tolerance of liver transplant patients to strenuous physical activity in high-altitude. 2004 Am. J. Transplant. pmid:15023147
Heisel O et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. 2004 Am. J. Transplant. pmid:15023151
Hardinger KL et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. 2004 Am. J. Transplant. pmid:15023155
Suwelack B et al. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. 2004 Am. J. Transplant. pmid:15023160
Madariaga ML et al. Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. 2015 Am. J. Transplant. pmid:25824550
Bryan CF et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. 2007 Am. J. Transplant. pmid:17359511
Vincenti F et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. 2007 Am. J. Transplant. pmid:17359512
Busque S et al. Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. 2009 Am. J. Transplant. pmid:19660021
Meier-Kriesche HU et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. 2005 Am. J. Transplant. pmid:16095509
Senior PA et al. Proteinuria developing after clinical islet transplantation resolves with sirolimus withdrawal and increased tacrolimus dosing. 2005 Am. J. Transplant. pmid:16095517
Tremblay S et al. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. 2017 Am. J. Transplant. pmid:27340950
Hardinger KL et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. 2010 Am. J. Transplant. pmid:20055811
De Simone P et al. Everolimus with reduced tacrolimus in liver transplantation. 2013 Am. J. Transplant. pmid:23601137
Fan DM et al. Successful ABO-incompatible living-related intestinal transplantation: a 2-year follow-up. 2015 Am. J. Transplant. pmid:25808777
Froud T et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. 2005 Am. J. Transplant. pmid:15996257
Borrows R et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. 2006 Am. J. Transplant. pmid:16433766
Chodoff L and Hamberg KJ Response to 'Different preparations of tacrolimus and medication errors'. 2009 Am. J. Transplant. pmid:19392982
Kohnle M et al. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. 2006 Am. J. Transplant. pmid:16433776
Cherukuri A et al. An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation. 2012 Am. J. Transplant. pmid:22390816
Larson TS et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. 2006 Am. J. Transplant. pmid:16468960
Pascher A et al. Protein kinase C inhibitor sotrastaurin in de novo liver transplant recipients: a randomized phase II trial. 2015 Am. J. Transplant. pmid:25677074
Vitko S et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. 2006 Am. J. Transplant. pmid:16468962
Barth RN et al. Vascularized bone marrow-based immunosuppression inhibits rejection of vascularized composite allografts in nonhuman primates. 2011 Am. J. Transplant. pmid:21668624
Chen G et al. A synergistic effect between PG490-88 and tacrolimus prolongs renal allograft survival in monkeys. 2006 Am. J. Transplant. pmid:16539628
Guirado L et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. 2011 Am. J. Transplant. pmid:21668633
Maes BD et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. 2002 Am. J. Transplant. pmid:12484345
Heller T et al. Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. 2007 Am. J. Transplant. pmid:17532750
Schrepfer S et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. 2007 Am. J. Transplant. pmid:17532751
Grenda R et al. A randomized trial to assess the impact of early steroid withdrawal on growth in pediatric renal transplantation: the TWIST study. 2010 Am. J. Transplant. pmid:20420639
Knechtle SJ et al. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. 2009 Am. J. Transplant. pmid:19344431
Grinyo JM et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. 2004 Am. J. Transplant. pmid:15268733
Pallet N et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. 2015 Am. J. Transplant. pmid:25588704
Schussler T et al. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. 2004 Am. J. Transplant. pmid:15268744
Min SI et al. Conversion of twice-daily tacrolimus to once-daily tacrolimus formulation in stable pediatric kidney transplant recipients: pharmacokinetics and efficacy. 2013 Am. J. Transplant. pmid:23734831
Bunnapradist S et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. 2013 Am. J. Transplant. pmid:23279614
Ceschi A et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. 2013 Am. J. Transplant. pmid:23279718
Toso C et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. 2006 Am. J. Transplant. pmid:16611343
Lacaille F et al. Severe dysimmune cytopenia in children treated with tacrolimus after organ transplantation. 2006 Am. J. Transplant. pmid:16611346
Chamie K et al. The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer. 2008 Am. J. Transplant. pmid:18853950
Tedesco-Silva H et al. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. 2015 Am. J. Transplant. pmid:25988935
Pech T et al. Intestinal regeneration, residual function and immunological priming following rescue therapy after rat small bowel transplantation. 2012 Am. J. Transplant. pmid:22974463
Kaplan B and Kirk AD Tacrolimus and sirolimus: when bad things happen to good drugs. 2006 Am. J. Transplant. pmid:16827845
McAlister VC et al. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. 2006 Am. J. Transplant. pmid:16827858
Gallon L et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. 2006 Am. J. Transplant. pmid:16827862
Grenda R et al. A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. 2006 Am. J. Transplant. pmid:16827869
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Pradhan M et al. Decline in renal function following thoracic organ transplantation in children. 2002 Am. J. Transplant. pmid:12201367
Rush D et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. 2007 Am. J. Transplant. pmid:17908280
Lake JR et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. 2005 Am. J. Transplant. pmid:16303011
Barbas AS et al. Posterior reversible encephalopathy syndrome independently associated with tacrolimus and sirolimus after multivisceral transplantation. 2013 Am. J. Transplant. pmid:23331705
Gatault P et al. Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. 2017 Am. J. Transplant. pmid:27862923
Fujishiro J et al. Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation. 2010 Am. J. Transplant. pmid:20642681
Margreiter R et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. 2008 Am. J. Transplant. pmid:18510632
Martinez F et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. 2010 Am. J. Transplant. pmid:20642691